EFFICACY OF MIRIKIZUMAB IN RESOLVING ACTIVE HISTOLOGIC INFLAMMATION IN ULCERATIVE COLITIS IN LUCENT-1 INDUCTION AND LUCENT-2 MAINTENANCE TRIALS

Fernando Magro  ¹     Rish Pai  ²     Taku Kobayashi  ³     Vipul Jairath  ⁴     Florian Rieder  ⁵     Isabel Redondo  ⁶     Trevor Lissoos  ⁷     Nathan Morris  ⁷     Mingyang Shan  ⁷     Laurent Peyrin-Biroulet  ^8    
1 University Hospital São João, Porto, Portugal
² Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, United States
³ Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, Japan
⁴ Division of Gastroenterology, Department of Medicine, Western University, London, Canada
⁵ Department of Gastroenterology, Hepatology and Nutrition, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, United States
⁶ Eli Lilly Portugal, Produtos Farmacêuticos, Lda., Lisbon, Portugal
⁷ Eli Lilly and Company, Indianapolis, United States
⁸ University Hospital of Nancy, Nancy, France

Session
Clinical trials in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)